NASDAQ: AMRX
Amneal Pharmaceuticals Inc Stock

$7.66-0.09 (-1.16%)
Updated Apr 30, 2025
AMRX Price
$7.66
Fair Value Price
N/A
Market Cap
$2.37B
52 Week Low
$5.81
52 Week High
$9.48
P/E
-20.16x
P/B
-21.73x
P/S
0.88x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.79B
Earnings
-$116.89M
Gross Margin
36.5%
Operating Margin
5.75%
Profit Margin
-4.2%
Debt to Equity
-33.05
Operating Cash Flow
$295M
Beta
1.14
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

AMRX Overview

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine AMRX's potential to beat the market

AStrong Buy
  • Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More

Zen Rating Component Grades

B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
AMRX
Ranked
#1 of 57

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$32.48A
$26.90A
$14.85A
View Top Pharmaceutical Stocks

Be the first to know about important AMRX news, forecast changes, insider trades & much more!

AMRX News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AMRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AMRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AMRX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AMRX's Earnings (EBIT) of $160.57M... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AMRX due diligence checks available for Premium users.

Valuation

AMRX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-20.16x
Industry
21.23x
Market
29.18x

AMRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-21.73x
Industry
2.09x

AMRX's financial health

Profit margin

Revenue
$730.5M
Net Income
-$31.1M
Profit Margin
-4.3%
AMRX's Earnings (EBIT) of $160.57M... subscribe to Premium to read more.
Interest Coverage Financials
AMRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$3.5B
Liabilities
$3.6B
Debt to equity
-33.05
AMRX's short-term assets ($1.59B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMRX's long-term liabilities ($2.48B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AMRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$118.1M
Investing
-$16.1M
Financing
-$61.2M
AMRX's operating cash flow ($295.10M)... subscribe to Premium to read more.
Debt Coverage Financials

AMRX vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
AMRXA$2.37B-1.16%-20.16x-21.73x
ALVOC$2.37B-0.25%-9.01x-5.73x
HCMA$2.59B-2.04%74.25x3.41x
BHCC$1.95B-3.81%-40.77x-1.52x
SUPNA$1.81B-0.03%24.24x1.75x

Amneal Pharmaceuticals Stock FAQ

What is Amneal Pharmaceuticals's quote symbol?

(NASDAQ: AMRX) Amneal Pharmaceuticals trades on the NASDAQ under the ticker symbol AMRX. Amneal Pharmaceuticals stock quotes can also be displayed as NASDAQ: AMRX.

If you're new to stock investing, here's how to buy Amneal Pharmaceuticals stock.

What is the 52 week high and low for Amneal Pharmaceuticals (NASDAQ: AMRX)?

(NASDAQ: AMRX) Amneal Pharmaceuticals's 52-week high was $9.48, and its 52-week low was $5.81. It is currently -19.16% from its 52-week high and 31.84% from its 52-week low.

How much is Amneal Pharmaceuticals stock worth today?

(NASDAQ: AMRX) Amneal Pharmaceuticals currently has 309,966,341 outstanding shares. With Amneal Pharmaceuticals stock trading at $7.66 per share, the total value of Amneal Pharmaceuticals stock (market capitalization) is $2.37B.

Amneal Pharmaceuticals stock was originally listed at a price of $19.30 in Mar 27, 2018. If you had invested in Amneal Pharmaceuticals stock at $19.30, your return over the last 7 years would have been -60.31%, for an annualized return of -12.37% (not including any dividends or dividend reinvestments).

How much is Amneal Pharmaceuticals's stock price per share?

(NASDAQ: AMRX) Amneal Pharmaceuticals stock price per share is $7.66 today (as of Apr 30, 2025).

What is Amneal Pharmaceuticals's Market Cap?

(NASDAQ: AMRX) Amneal Pharmaceuticals's market cap is $2.37B, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Amneal Pharmaceuticals's market cap is calculated by multiplying AMRX's current stock price of $7.66 by AMRX's total outstanding shares of 309,966,341.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.